Randomized trial of mefloquine alone and artesunate followed by mefloquine for the treatment of acute uncomplicated falciparum malaria.
Randomized trial of mefloquine alone and artesunate followed by mefloquine for the treatment of acute uncomplicated falciparum malaria.
复制标题
单独使用甲氟喹和青蒿琥酯随后使用甲氟喹治疗急性单纯性恶性疟疾的随机试验。
DOI：
10.1080/00034983.1994.11812850
复制
发表时间：
1994
影响因子：
--
通讯作者：
M. Andrial
中科院分区：
文献类型：
--
作者：
S. Looareesuwan;S. Vanijanonta;C. Viravan;P. Wilairatana;P. Charoenlarp;M. Andrial
甲氟喹是泰国疟疾诊所用于治疗恶性疟疾患者的主要抗疟药。然而，近年来单用甲氟喹的治愈率严重下降。因此，在一项涉及125例急性无并发症恶性疟疾患者的随机治疗试验中，将青蒿琥酯随后甲氟喹序贯治疗的疗效和耐受性与甲氟喹单独治疗的疗效和耐受性进行了比较。63名患者接受甲氟喹单独治疗（立即给予750 mg，6小时后给予500 mg），62名患者接受青蒿琥酯800 mg治疗2天（每12小时200 mg），6小时后给予单次750 mg剂量的甲氟喹。所有患者均在曼谷的医院住院28天，以排除再次感染。大多数患者（107例）完成了研究; 18例患者在完成随访前因与治疗无关的原因离开医院。两组治愈率分别为单用甲氟喹74%（42/57）和青蒿琥酯加用甲氟喹92%（46/50）。序贯联合治疗组的平均寄生虫清除时间明显短于甲氟喹单药治疗组（P < 0.001），但平均发热清除时间无显著差异（P = 0.26）。大多数患者对治疗方案反应良好，无严重毒性不良反应。仅4名仅接受甲氟喹治疗的患者的寄生虫血症持续至第7天（RII），因此需要替代随访治疗。（250字处删节）
Mefloquine is the main antimalarial used for treatment of falciparum malaria patients at the malaria clinics in Thailand. However, the cure rate with mefloquine alone has declined seriously in recent years. The efficacy and tolerability of a sequential treatment of artesunate followed by mefloquine was therefore compared with those of mefloquine alone, in a randomized therapeutic trial involving 125 patients with acute uncomplicated falciparum malaria. Sixty-three patients received mefloquine alone (750 mg given immediately, followed by 500 mg 6 h later) and 62 each received 800 mg artesunate over 2 days (200 mg every 12 h) followed 6 h later by a single, 750-mg dose of mefloquine. All patients were admitted to the hospital in Bangkok for 28 days to exclude re-infection. Most patients (107) completed the study; 18 left the hospital prior to completion of follow-up for reasons unrelated to their treatment. Cure rates for the two groups were 74% (42/57) for mefloquine alone and 92% (46/50) for artesunate followed by mefloquine. The mean parasite clearance time was significantly shorter (P < 0.001) in the group treated with the sequential combination than in the group treated with mefloquine alone, but the mean fever clearance times were not significantly different (P = 0.26). Most patients responded well to the treatment regimens and none suffered from serious toxic adverse reactions. Only four patients who were treated with mefloquine alone had parasitaemia persisting to day 7 (RII), thus requiring alternative follow-up treatment.(ABSTRACT TRUNCATED AT 250 WORDS)